Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 39kWORD 9k
24 April 2020
E-002489/2020
Question for written answer
to the Commission
Rule 138
Joëlle Mélin
 Answer in writing 
 Subject: Controls on medical products at the EU borders

The exceptional situation created by the global COVID-19 pandemic has demonstrated how effective borders are, and the need for them, as it is clearly because borders have disappeared that the virus has been able to spread. Sick people and healthy carriers of the virus moved out from the pandemic’s Chinese epicentre, infecting every region in the world.

The Member States’ borders act as filters making it possible to apprehend threats and dangers that try to enter the EU. In the health field, COVID-19 has revealed the deep flaws in our EU health system, and in particular concerning medicine stocks.

More worrying still, the European Observatory on Infringements of Intellectual Property Rights has published a report on the economic cost of counterfeit medicinal products (4.4 % of medicines on the market), which confirms figures on the number of counterfeit or defective medical products (masks, gowns, etc.) from non-EU countries, on account of our dependence on imports of medicines and medical products.

Under these conditions, will the Commission strengthen controls at the EU’s borders for pharmaceutical and medical products, and does it envisage assisting Member States in relocating their production of medicines and medical products?

Original language of question: FR
Last updated: 8 May 2020Legal notice - Privacy policy